---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-107031"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:15:46.860732+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Athira cuts 70% of workforce, pivots to ATH-1105 after LIFT-AD readout

## Summary
- Workforce reduction of ~70% (49 positions); one-time costs ~$2.8M third-quarter 2024.
- Annualized cost savings ~$13.4M; cash runway extended into Q1 2026.
- CFO Andrew Gengos and COO Rachel Lenington terminated without cause, effective Oct 1, 2024.
- VP Finance Robert Renninger appointed principal financial and accounting officer.
- Focus shifts to ATH-1105 (oral HGF modulator) for ALS; Phase 1 completes by year-end 2024.

## SEC filing metadata
- accession: 0000950170-24-107031
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017024107031/0000950170-24-107031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017024107031/atha-20240915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-107031
- JSON: https://secwatch.observer/filing/0000950170-24-107031.json
- Plain text: https://secwatch.observer/filing/0000950170-24-107031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.